Compare Adaptive Biotechnologies Corp (ADPT) vs Ulta Beauty Inc (ULTA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Ulta Beauty Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.94 (market cap $3.33B), while Ulta Beauty Inc trades at $457.05 (market cap $19.51B). The key difference: Ulta Beauty Inc is far larger — about 5.9× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Ulta Beauty Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | ULTA | |
|---|---|---|
Market Cap | $3.33B | $19.51B |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $706.82 |
52-Week Low | $10.24 | $450.75 |
Enterprise Value | $3.19B | $21.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
ULTA Beauty trades at $453.78, down 1.64% recently, with a bearish technical signal from moving averages but oversold RSI near 29. The stock shows strong profitability with a 9.36% net margin and 47.45% ROE, though revenue growth slowed to $11.3B in 2025. Recent news highlights partnerships with Bath & Body Works and AI-driven loyalty initiatives to boost engagement.
Analysts remain bullish with a $623.73 consensus target, citing valuation discounts and market share gains. Risks include competitive pressures and margin compression, but the current P/E of 16.96 offers value if execution improves. The stock presents a contrarian opportunity amid negative sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Ulta Beauty Inc
With more than 1,300 stores and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the U.S. The firm offers makeup (43% of 2021 sales), fragrances, skin care, and hair care products (20% of 2021 sales), and bath and body items. Ulta offers private-label products and merchandise from more than 500 vendors. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
Read more on ULTA →
